ity) to assess renal outcomes, the groups were similar with respect to fracture-specific risk factors at baseline. Our study was observational; while the 2 groups were well matched on important prognostic factors such as dementia and psychoses, the associations may be subject to confounding by indication in which the reason for prescription of an atypical antipsychotic medication (eg, behavioral disturbances) may predispose patients to falls and fractures.

In summary, these findings call into question the widespread off-label use of atypical antipsychotic medications and support increasing evidence of safety concerns regarding their use in older adults.

Lisa-Ann Fraser, MD, MSc
Kuan Liu, MMath
Kyla L. Naylor, MES
Y. Joseph Hwang, MSc
Stephanie N. Dixon, PhD
Salimah Z. Shariff, PhD
Amit X. Garg, MD, PhD

Author Affiliations: Department of Medicine, University of Western Ontario, London, Ontario, Canada (Fraser, Garg); Institute for Clinical Evaluative Sciences, Western Satellite Site, London, Ontario, Canada (Liu, Dixon, Shariff, Garg); Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada (Naylor; Hwang, Garg); Case Western Reserve University School of Medicine, Cleveland, Ohio (Hwang).

Corresponding Author: Lisa-Ann Fraser, MD, MSc, Department of Medicine, University of Western Ontario, 268 Grosvenor’s St, London, ON N6A 4V2, Canada.


Author Contributions: Dr Shariff had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Fraser, Shariff, Garg.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Fraser.

Critical revision of the manuscript for important intellectual content: Liu, Naylor, Hwang, Dixon, Shariff, Garg.

Statistical analysis: Liu, Hwang, Dixon, Shariff.

Obtained funding: Garg.

Administrative, technical, or material support: Fraser, Naylor, Garg.

Study supervision: Shariff.

Conflict of Interest Disclosures: Dr Garg reports receiving an investigator-initiated grant from Astellas and Roche to support a Canadian Institutes of Health Research study in living kidney donors, and that his institution received unrestricted research funding from Pfizer. No other disclosures were reported.

Funding/Sponsor: This study was supported by the Institute for Clinical Evaluative Sciences (ICES) Western Site. ICES is funded by a annual grant from the Ontario Ministry of Health and Long-Term Care. The ICES Western Site is funded by an operating grant from the Academic Medical Organization of Southwestern Ontario, the Schulich School of Medicine and Dentistry at Western University, and the Lawson Health Research Institute.

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The study design and conduct, opinions, results, and conclusions in this article are those of the authors and are independent of the funding sources.


Orders for Intravenous Proton Pump Inhibitors After Implementation of an Electronic Alert

Proton pump inhibitors (PPIs) are highly effective in treating gastric acid-related disorders but are often overused. Intravenous (IV) PPIs are expensive compared with oral PPIs and have few absolute indications; more than half of hospitalized patients prescribed IV PPIs could instead receive oral PPIs. Health information technologies have the potential to improve physician ordering of medications but have not been applied to IV PPIs.

Methods | This study was approved by the institutional review board of Columbia University with a waiver of consent. On October 21, 2011, our institution (Columbia University Medical Center) introduced an alert that was triggered by all IV PPI orders, excluding continuous infusion PPIs. Esomeprazole is our institution’s only formulary PPI; therefore, the alert applied only to orders for esomeprazole. The alert explains that oral PPIs cost one-tenth as much as IV PPIs, yet they are 90% bioavailable. The response of health care professionals to the alert was automatically captured. Our primary outcome was a change in the proportion of all PPIs given intravenously during 1 year before the alert compared with 1 year after the alert, which we assessed retrospectively using an interrupted time-series analysis. No other interventions were made related to PPI ordering during the study period. Multivariable logistic regression modeling was performed to assess predictors of an IV compared with an oral PPI order, stratified by alert period. To characterize orders in terms of indications, we randomly selected 50 medical records from before alert implementation and 50 medical records from after alert implementation. We then classified IV PPI orders as indicated or not indicated based on criteria derived from current guidelines.

Results | During the 2-year study period, there were 65 078 completed orders for PPIs, including 10 050 of 33 520 orders (30.0%) for IV PPIs before alert implementation and 72 47 of 31 580 orders (23.0%) for IV PPIs after implementation (χ² test, P < .0001), representing a 7.0% absolute and 23.4% relative reduction in the proportion of IV PPIs (Figure). During the year before the alert, the proportion of IV PPI orders completed decreased a mean of 0.7% monthly (P = .049). After adjusting for the trend in IV PPI use before the alert, the proportion of IV PPI orders completed remained significantly decreased after implementa-
Figure. Proportion of Intravenous (IV) Proton Pump Inhibitors (PPIs) Given Before and After Implementation of an Electronic Alert, November 2010-October 2012

The alert was implemented on October 21, 2011.

Table. Multivariable Logistic Regression Analysis for Odds of Completing an IV Compared With an Oral PPI Order, Stratified by Alert Period

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Before Alert Implementation</th>
<th>After Alert Implementation</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total No. of PPI Orders</td>
<td>No. (%) of IV Orders</td>
</tr>
<tr>
<td>Total</td>
<td>33 520</td>
<td>10 050 (30.0)</td>
</tr>
<tr>
<td>Order frequency</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Once daily or less</td>
<td>30 142</td>
<td>8 474 (28.1)</td>
</tr>
<tr>
<td>More than once daily</td>
<td>3 378</td>
<td>1 576 (46.7)</td>
</tr>
<tr>
<td>Service</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicine</td>
<td>19 796</td>
<td>5 637 (28.5)</td>
</tr>
<tr>
<td>Surgery</td>
<td>9 783</td>
<td>3 599 (36.8)</td>
</tr>
<tr>
<td>Neurology</td>
<td>2 953</td>
<td>5 26 (17.8)</td>
</tr>
<tr>
<td>Obstetrics-gynecology</td>
<td>6 47</td>
<td>2 80 (43.3)</td>
</tr>
<tr>
<td>Psychiatry</td>
<td>3 41</td>
<td>8 (2.3)</td>
</tr>
<tr>
<td>Health care professional role</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Physician</td>
<td>25 950</td>
<td>8 023 (30.9)</td>
</tr>
<tr>
<td>NP or PA</td>
<td>7 480</td>
<td>2 019 (27.0)</td>
</tr>
<tr>
<td>Medical student</td>
<td>90</td>
<td>8 (8.9)</td>
</tr>
<tr>
<td>Order set</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>27 583</td>
<td>6 700 (24.3)</td>
</tr>
<tr>
<td>Yes</td>
<td>5 937</td>
<td>3 350 (56.4)</td>
</tr>
<tr>
<td>Diet status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Any diet</td>
<td>14 277</td>
<td>1 542 (10.8)</td>
</tr>
<tr>
<td>NPO</td>
<td>7 859</td>
<td>5 164 (65.7)</td>
</tr>
<tr>
<td>No order</td>
<td>11 389</td>
<td>3 344 (29.4)</td>
</tr>
</tbody>
</table>

Abbreviations: IV, intravenous; NA, not applicable; NPO, nothing by mouth; NP, nurse practitioner; OR, odds ratio; PA, physician assistant; PPI, proton pump inhibitor.
tation of the alert ($P < .001$). Health care professional-level factors were significant predictors of IV compared with oral PPI administration, including the presence of the PPI within an order set (Table). There was improved indication after implementation of the alert, but the findings were not significant (88.0% indicated after vs 74.0% before; $P = .07$). On the basis of the institutional cost differences between IV and oral PPIs and the observed reduction in IV PPI orders during the year after the alert, we estimate a $450,692 annual decrease in institutional costs related to IV PPI use.

Discussion | Intravenous PPIs are frequently given in situations in which oral PPIs would suffice. We found that implementation of an electronic alert for IV PPI orders was associated with a 23.0% relative decrease in the proportion of orders of PPI. This result was significant after adjusting for the trend in the proportion of IV PPIs ordered before implementation of the alert. The decrease in the proportion of IV PPIs ordered was immediate, sustained, accompanied by an overall decrease in IV PPI orders, and associated with significant cost savings.

Few prior data on electronic interventions seeking to improve PPI use are available. In the outpatient setting, pharmacist-based electronic interventions may reduce overall PPI use. Inpatient studies have evaluated the use of computerized decision support in changing IV to oral medication orders but have not targeted IV PPIs. Our findings suggest that, if health care professionals are educated to make a clearly defined change with a simple but focused alert, oral PPIs will frequently be substituted for IV PPIs. Health care professional-level factors were also an important determinant of PPI route of administration. Compared with the medical service, the surgery or obstetrics-gynecology services were more likely to order IV vs oral PPIs. This was true before and after the alert and after adjusting for patient diet status; however, this study was not designed to address the reasons underlying these differences. Notably, presence of the IV PPI within an order set strongly predicted IV compared with oral PPI use before and after alert implementation.

Our study highlights the potential for electronic alerts to alter ordering behavior for IV PPIs. Institutions seeking to decrease IV PPI use should consider removing IV PPIs from order sets, and future studies should test whether additional targeted interventions using clinical decision support systems can improve PPI overuse.

Daniel E. Freedberg, MD, MS
Hojjat Salmasian, MD, MPH
Julian A. Abrams, MD, MS
Robert A. Green, MD, MPH

Author Affiliations: Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Medical Center, New York, New York (Freedberg, Abrams); Department of Biomedical Informatics, Columbia University Medical Center, New York, New York (Salmasian); Department of Emergency Medicine, Columbia University Medical Center and New York–Presbyterian Hospital, New York, New York (Green).

Corresponding Author: Daniel E. Freedberg, MD, MS, Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Medical Center, 630 W 168th St, PH Bldg, Floor 20, New York, NY 10032 (def2004@columbia.edu).


Author Contributions: Dr Freedberg had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Freedberg, Abrams, Green. Acquisition, analysis, or interpretation of data: Freedberg, Salmasian, Abrams. Drafting of the manuscript: All authors. Critical revision of the manuscript for important intellectual content: Freedberg, Salmasian, Abrams. Statistical analysis: Freedberg, Abrams, Green. Administrative, technical, or material support: Freedberg, Abrams, Green. Study supervision: Freedberg, Abrams.

Conflict of Interest Disclosures: None reported.

Funding/Support: This study was supported in part by grants UL1 TR000140 and UL1 RR024156 from the National Center for Advancing Translational Sciences (formerly the National Center for Research Resources) (Dr Freedberg), training grant T32 DK083256-0 from the National Institute of Diabetes and Digestive and Kidney Diseases (Dr Freedberg), training grant T15 LM007079 from the National Library of Medicine (Dr Salmasian), and Career Development Award K07 CA 132892 from the National Cancer Institute (Dr Abrams).

Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.

Previous Presentation: This study was presented at the Annual Conference of the American College of Gastroenterology, October 13, 2013; San Diego, California.

Additional Contributions: Alfred I. Neugut, MD, PhD, provided thoughtful comments on the manuscript during revision. No financial compensation was provided.

5. Smeets HM, Hoes AW, de Wit NJ. Effectiveness and costs of implementation strategies to reduce acid suppressive drug prescriptions: a systematic review. BMC Health Serv Res. 2007;7:177.

Population Trends in Rates of Coronary Revascularization

Improvements in prevention have led to declines in rates of myocardial infarction (MD). Simultaneously, evidence from randomized trials has confirmed the role of medical therapy as a first-line treatment for stable coronary disease. Together, these forces could lead to significant declines in population-wide rates of coronary revascularization. We examined recent temporal trends in population rates of coronary revascularization using comprehensive clinical data collected in Massachusetts.